Diosmetin protects against DSS-induced colitis in vivo
We first evaluated the effects of diosmetin treatment on DSS (the
concentration of 3% and
5%)-induced colitis, and the
experimental program is shown in Fig. 1A, B.
As shown in Fig. 1C, the
body weight was decreased
apparently and the
DAI
score increased rapidly with the treatment of DSS. After stopping
drinking DSS, the body weight was recovered gradually and the DAI score
decreased. As shown in Fig. 1D, compared to DSS only group, the body
weight in mice treated with
diosmetin was higher and DAI score
was lower. As shown in Fig.1E, F, compared with control group, the
length of colon significantly shorten in DSS only group, however the
length of colon observably become longer in DSS with
diosmetin group compared to DSS
group. As shown in Figure 1G, H, (200× magnification) the
histopathological changes including the
inflammatory infiltration,
disappearance of goblet cells and superficial epithelial cells and edema
between mucosal and muscular layers, in the groups treated with DSS
only, were all markedly reversed by SASP and diosmetin.
As shown in Figure 1I, K, the viability of caco2 and IEC-6 cells was
increased
or decreased without any significant difference compared to that of
control group after treatment with
diosmetin (25–400 μM) for 6–24 h,
which revealed that diosmetin was non-toxic to caco2 and IEC-6 cells
under such conditions. As shown in Figure 1G, L, exposure to LPS
(0.125–32 μg /mL) for 24 h induced the viability of caco2 and IEC-6
cells slightly increased or decreased without any significant difference
compared with the control groups. These results indicated that
diosmetin markedly alleviated
DSS-induced colitis and was non-toxic to caco2 and IEC-6 cells.